Sanofi’s Nexviazyme Meets Primary And Secondary Endpoints In Phase 3 Study For Infantile-Onset Pompe Disease
To Submit US Regulatory Application For Nexviazyme In Infantile-Onset Pompe Disease
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.